354 related articles for article (PubMed ID: 27284123)
1. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
[TBL] [Abstract][Full Text] [Related]
2. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.
Qiao JH; Jiao DC; Lu ZD; Yang S; Liu ZZ
Tumour Biol; 2015 Sep; 36(9):6833-8. PubMed ID: 25846735
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.
Won HS; Lee KE; Sung SH; Choi MY; Jo JY; Nam EM; Mun YC; Seong CM; Lee SN
Tumori; 2014; 100(1):80-6. PubMed ID: 24675496
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
[TBL] [Abstract][Full Text] [Related]
6. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
7. Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy.
Nikolényi A; Uhercsák G; Csenki M; Hamar S; Csörgo E; Tánczos E; Thurzó L; Brodowicz T; Wagnerova M; Kahán Z
Pathol Oncol Res; 2012 Jan; 18(1):61-8. PubMed ID: 21681601
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
9. Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer.
Nakagawa M; Bando Y; Nagao T; Morimoto M; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Sasa M; Tangoku A
Anticancer Res; 2011 Jun; 31(6):2389-93. PubMed ID: 21737670
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of insulin-like growth factor-1 receptor expression in breast cancer.
Şahin S; Cakir A; Gonul II; Seckin S; Uluoglu O
Ann Ital Chir; 2020; 91():583-591. PubMed ID: 33554951
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
An X; Xu F; Luo R; Zheng Q; Lu J; Yang Y; Qin T; Yuan Z; Shi Y; Jiang W; Wang S
BMC Cancer; 2018 Mar; 18(1):331. PubMed ID: 29587760
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of survivin and DNA topoisomerase IIα in diffuse and anaplastic astrocytomas.
Varughese RK; Skjulsvik AJ; Torp SH
Pathol Res Pract; 2017 Apr; 213(4):339-347. PubMed ID: 28214203
[TBL] [Abstract][Full Text] [Related]
14. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
Wu Y; Han Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Xu H; Wang Y; Ma F; Wang J; Xu B
Breast Cancer Res Treat; 2022 Jun; 193(2):381-392. PubMed ID: 35297009
[TBL] [Abstract][Full Text] [Related]
16. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
Jensen JD; Knoop A; Ewertz M; Laenkholm AV
Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
[TBL] [Abstract][Full Text] [Related]
17. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
[TBL] [Abstract][Full Text] [Related]
18. Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.
Chen JR; Chien HP; Chen KS; Hwang CC; Chen HY; Yeh KY; Hsieh TY; Chang LC; Hsu YC; Lu RJ; Hua CC
Medicine (Baltimore); 2017 Jan; 96(2):e5582. PubMed ID: 28079792
[TBL] [Abstract][Full Text] [Related]
19. Proliferation index revisited in neuroblastic tumors.
Iżycka-Świeszewska E; Lipska-Ziętkiewicz BS; Adamkiewicz-Drożyńska E; Grajkowska W; Hermann B; Bień E; Limon J
Folia Neuropathol; 2014; 52(3):243-52. PubMed ID: 25310735
[TBL] [Abstract][Full Text] [Related]
20. CD99 correlates with low cyclin D1, high topoisomerase 2 status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma.
Czapiewski P; Wełnicka-Jaśkiewicz M; Seroczyńska B; Skokowski J; Sejda A; Szade J; Wiewiora C; Biernat W; Żaczek A
Pol J Pathol; 2015 Sep; 66(3):269-75. PubMed ID: 26619106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
